Steven Bloom Appointed Chief Business Officer at Werewolf Therapeutics
Werewolf Therapeutics, Inc. (Nasdaq: HOWL), a leading innovator in the biopharmaceutical sector, is excited to announce the appointment of Steven Bloom as its new Chief Business Officer. With over 35 years of extensive experience in the life sciences field, Mr. Bloom is set to make significant contributions to the company’s ongoing development of cutting-edge therapeutics.
Building on Veteran Expertise
Mr. Bloom's impressive background includes various leadership roles focused on corporate development, commercial planning, and strategic consulting. According to Daniel J. Hicklin, Ph.D., the President and CEO of Werewolf, Mr. Bloom's expertise is particularly critical at this time as Werewolf prepares for essential milestones in its clinical trials.
The company is on the verge of a pivotal year, as interim dose expansion data from the WTX-124 Phase 1/1b clinical trial is anticipated. This data is expected to facilitate discussions with regulators concerning possible registrational pathways. Werewolf’s innovative PREDATOR platform is also progressing well, leading to the development of novel molecules targeting oncology and immunology.
Stepping In from Vincerx Pharma
Before joining Werewolf, Steven Bloom held the position of Chief Business Officer at Vincerx Pharma, Inc. During his tenure, he played a key role in business development and corporate strategy, helping to stabilize the company through various transaction initiatives. His previous experience includes leadership roles at notable biotechnology firms such as Ziopharm Oncology and Verastem Oncology, positioning him as a seasoned expert in the industry.
Bloom’s history also includes senior positions at Eli Lilly and Company, where his efforts were focused on sales and marketing, patient advocacy, and corporate affairs. His diverse background equips him with the knowledge to drive Werewolf's initiatives forward.
Werewolf’s Commitment to Innovation
Addressing the crucial need for more effective cancer treatments, Mr. Bloom highlighted the company's transformative approach to cancer immunotherapy. He stated, "Werewolf is positioning itself to change the way cancer is treated through its novel immunotherapy technology designed to target tumors while minimizing side effects for patients." The lead program, WTX-124, has shown promising durable responses in patients, and the company is excited to expand its pipeline utilizing the PREDATOR technology.
Bloom expressed his enthusiasm for joining an accomplished team at Werewolf, stating, "I am thrilled to join this experienced team and look forward to working with Werewolf to advance its products." This dedication to innovation is at the heart of Werewolf’s mission to redefine cancer therapies.
A Focus on Community Involvement
Mr. Bloom is not only a distinguished professional but also dedicated to community service. He graduated from Northeastern University School of Pharmacy and has been involved with the American Cancer Society's Road to Recovery program since 2008. Furthermore, he serves as the Chair of the Board of Directors for the CLL Society, which is committed to addressing the challenges faced by the chronic lymphocytic leukemia community through education, advocacy, and research.
Stock Options and Incentives
As part of Mr. Bloom’s induction into Werewolf, the board of directors approved a stock option grant as an incentive for his role. This grant covers up to 201,720 shares of the company’s common stock at an exercise price aligned with the market price on May 1, 2025. The stock option is designed to encourage Mr. Bloom’s ongoing contribution to the company, with options vesting over a set timeline.
About Werewolf Therapeutics
Werewolf Therapeutics, Inc. pioneers the development of groundbreaking therapeutics designed to stimulate the immune system for the treatment of cancer and other immune-related diseases. Specializing in conditionally activated molecules, the company is committed to minimizing the drawbacks of traditional immune therapies while enhancing therapeutic efficacy. Currently, the advanced product candidates, WTX-124 and WTX-330, demonstrate promise in treating various solid tumors.
Frequently Asked Questions
What role has Steven Bloom taken at Werewolf Therapeutics?
Steven Bloom has been appointed as the Chief Business Officer, bringing extensive experience in the life sciences industry.
What is the focus of Werewolf Therapeutics?
Werewolf Therapeutics focuses on developing conditionally activated therapeutics to enhance the body’s immune response against cancer and other immune-mediated conditions.
How does Werewolf's PREDATOR platform work?
The PREDATOR platform is designed to create therapeutics that activate the immune system in the tumor microenvironment while remaining inactive in peripheral tissues.
What is WTX-124?
WTX-124 is Werewolf's lead program and is a conditionally activated Interleukin-2 molecule targeted at treating solid tumors. Clinical results have shown promising durable responses in patients.
How is Steven Bloom involved with community initiatives?
Beyond his professional work, Bloom has been a volunteer driver for the American Cancer Society and contributes to advocacy efforts through his role with the CLL Society.
